{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"181","value":"15.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 1 Hour Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.4","value":"16.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 4 Hours Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.5","value":"2.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Cycle 1 Day 8: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.6","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 1 Day 15: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.8","value":"2.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.5","value":"4.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Cycle 2 Day 8: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.9","value":"3.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.4","value":"3.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.1","value":"3.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Cycle 5 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.9","value":"5.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Cycle 5 Day 8: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.3","value":"3.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Cycle 6 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.5","value":"4.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Cycle 7 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.7","value":"3.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Cycle 8 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.3","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 9 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.6","value":"2.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 10 Day 1: Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"ISP=all participants who received atleast 1 dose of ixazomib. Number analyzed=participants with data available for analysis at specified time point. As prespecified in SAP, ISP had only 1 arm:Ixazomib (participants originally randomized to ixazomib + participants randomized to placebo arm prior to implementation of Amendment 08 \\& crossed over to ixazomib arm contributing data for this OM from time they initiated ixazomib onward), thus data is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)","title":"Plasma Concentration of Ixazomib","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}